Top Page
Circassia Pharmaceuticals
(LSE:NIOX)
Circassia Pharmaceuticals (NIOX) vs. iShares MSCI United Kingdom ETF (EWC)
Circassia Pharmaceuticals Business Overview & Revenue Model
Circassia Pharmaceuticals Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.80M | 36.80M | 31.30M | 27.90M | 23.90M |
| Gross Profit | 30.20M | 26.50M | 22.20M | 19.00M | 16.30M |
| EBITDA | 12.20M | 8.60M | 15.20M | 2.90M | -9.10M |
| Net Income | 3.70M | 10.70M | 16.10M | 3.60M | -33.50M |
Balance Sheet | |||||
| Total Assets | 68.40M | 91.50M | 98.50M | 86.40M | 103.10M |
| Cash, Cash Equivalents and Short-Term Investments | 10.90M | 19.90M | 19.40M | 12.60M | 7.40M |
| Total Debt | 1.50M | 1.10M | 1.00M | 1.30M | 1.60M |
| Total Liabilities | 8.90M | 7.70M | 16.60M | 19.60M | 37.00M |
| Stockholders Equity | 59.50M | 83.80M | 81.90M | 66.80M | 66.10M |
Cash Flow | |||||
| Free Cash Flow | 16.20M | 11.30M | 6.60M | 1.20M | -24.40M |
| Operating Cash Flow | 17.20M | 11.60M | 6.70M | 1.40M | -23.90M |
| Investing Cash Flow | -1.00M | -300.00K | -100.00K | -200.00K | -500.00K |
| Financing Cash Flow | -25.10M | -10.50M | -500.00K | 4.10M | 4.30M |
Circassia Pharmaceuticals Technical Analysis
Circassia Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ÂŁ283.84M | 77.27 | 4.55% | 136.69% | 13.59% | -66.27% | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
55 Neutral | £303.60M | 7.72 | 11.74% | ― | 38.80% | ― | |
51 Neutral | £347.95M | ― | -369.20% | ― | 4.50% | 74.32% | |
48 Neutral | AU$2.43B | 4.28 | -64.25% | 2.88% | 35.15% | 13.63% | |
43 Neutral | £119.90M | ― | -73.02% | ― | 41.15% | ― | |
| $460.01M | ― | -66.23% | ― | ― | ― |
Circassia Pharmaceuticals Corporate Events
NIOX Group plc, a company listed on AIM, has issued 144,844 new ordinary shares to Ian Johnson, the Non-Executive Chairman, under its Deferred Share Bonus Plan. This issuance relates to the annual bonus for the 2023 financial year, initially granted when Johnson was Executive Chairman. The deferral period for these shares was waived upon his transition to Non-Executive Chairman, allowing for the allotment of the shares. This transaction increases the total issued share capital of the company to 417,751,925 ordinary shares, impacting the voting rights and shareholding structure.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a UK-based issuer, has experienced a change in its voting rights structure due to an acquisition by Rathbones Investment Management Ltd. The acquisition has increased Rathbones’ voting rights in Niox Group PLC to 10.5228%, up from a previous position of 8.6953%. This change in voting rights indicates a significant shift in shareholder influence within the company, potentially impacting its strategic decisions and stakeholder relationships.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a UK-based company, has announced a change in its shareholder structure, with Rathbones Investment Management Ltd adjusting its voting rights. As of June 23, 2025, Rathbones’ voting rights in Niox Group PLC decreased from 10.7058% to 8.6953%. This change reflects a strategic decision by Rathbones and may impact Niox Group’s shareholder dynamics and influence within the company.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group PLC, a company involved in the pharmaceutical industry, has announced a change in its total voting rights due to share activity related to the company and two of its directors. This notification was made by AstraZeneca PLC, which now holds 15.86% of the voting rights in NIOX Group, a decrease from the previous 16.997%. The adjustment in voting rights could impact the company’s governance and influence within the industry, potentially affecting its strategic decisions and stakeholder interests.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group plc, a company listed on AIM, has announced an update regarding its total voting rights. As of May 31, 2025, the company has 417,417,579 Ordinary Shares in issue, each carrying one voting right, with no shares held in treasury. Recent exercises of employee share options have resulted in the issuance of 735,050 new Ordinary Shares, which have been admitted via block listing and rank equally with existing shares. This update is relevant for shareholders calculating their interest in the company under FCA’s rules.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a UK-based company, has undergone a change in its voting rights structure due to an acquisition or disposal by Danske Bank A/S, a financial institution based in Copenhagen, Denmark. The notification indicates that Danske Bank’s voting rights in Niox Group have decreased from 3.43072% to 2.99176%, as of May 23, 2025. This change reflects a shift in the company’s shareholder dynamics, potentially impacting its governance and decision-making processes.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group PLC has announced a change in its advisory team, with Singer Capital Markets now serving as the sole broker and continuing as the company’s Nominated Adviser. This strategic move is expected to streamline NIOX’s financial advisory services, potentially enhancing its market operations and positioning within the pharmaceutical industry.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a UK-based company, has experienced a change in the breakdown of its voting rights, as reported by Harwood Capital LLP. The notification indicates that Harwood Capital LLP’s voting rights in Niox Group have decreased from 17.8802% to 16.876%, reflecting a shift in shareholder influence.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group plc, a company involved in the healthcare sector, has announced a block listing application for 1,207,893 ordinary shares to be admitted to trading on AIM. This move is associated with the exercise of options under the company’s Performance Share Plan Scheme 2019 and Save As You Earn Plan 2022. The admission of these shares is expected to take effect on 28 May 2025, and they will rank equally with existing shares, potentially impacting the company’s market presence and shareholder value.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a UK-based company, has experienced a significant change in its shareholder structure. Rathbones Investment Management Ltd and Investec Wealth & Investment Limited have increased their voting rights in Niox Group PLC to 10.7058%, up from the previous 5.2724%. This acquisition of voting rights indicates a strategic move by these investment firms, potentially impacting the company’s governance and decision-making processes.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Niox Group PLC, a company involved in the pharmaceutical industry, has announced a change in its major holdings. Richard Griffiths and his controlled holdings have adjusted their voting rights in Niox Group PLC, resulting in a decrease from 8.91% to 5.96%. This change is attributed to the dilution on the issue of options and reflects a shift in the company’s shareholder structure, potentially impacting its governance and strategic decision-making.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group plc, a company listed on the AIM market, announced that its directors, Ian Johnson and Jonathan Emms, exercised share options awarded under the company’s Performance Share Plan. This exercise resulted in the issuance of 6,272,099 new ordinary shares and the transfer of 6,000,000 shares from treasury. To cover tax liabilities and other costs, the directors sold 6,670,555 shares at 65.0 pence each. The company’s issued share capital now consists of 416,682,529 ordinary shares, each carrying one voting right, with no shares held in treasury.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group plc reported a strong start to 2025 with a 21% increase in sales, driven by significant growth in its research business due to increased clinical trial activity. The company is prioritizing the expansion of FeNO testing in the US, the launch of the NIOX PRO® device, and the development of a home-use device. Despite a one-off cost from a withdrawn bid and upcoming board changes, NIOX remains optimistic about its financial health and strategic direction.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
NIOX Group plc, a company listed on the AIM market, has announced a timetable for its proposed final dividend for the financial year ending 31 December 2024. The dividend of 1.25 pence per share is subject to approval at the Annual General Meeting on 14 May 2025, with key dates including an ex-dividend date of 15 May 2025 and a payment date of 16 June 2025.
NIOX Group plc, a company listed on the AIM market, has announced the publication of its Notice of the 2025 Annual General Meeting on its website. The meeting is scheduled for May 14, 2025, at their registered office in Oxford, England, and shareholders have been sent copies of the 2024 Annual Report and Accounts if requested.
Niox Group PLC, a UK-based company, has announced a change in the breakdown of its voting rights due to an acquisition or disposal of financial instruments. Spreadex LTD, a regulated provider of spread betting and CFD trading, has adjusted its position in Niox Group, resulting in a decrease in its voting rights from 3.0694% to 2.4063%. This adjustment reflects a shift in the financial instruments held by Spreadex, impacting the overall voting influence within Niox Group.
NIOX Group plc, a company listed on the AIM market, announced a transaction involving Áinne Naylor, a Person Closely Associated with Robert Naylor, a Non-Executive Director. Áinne Naylor purchased 44,166 Ordinary Shares at £0.565 per share, increasing Robert Naylor’s total shareholding to 44,166 shares, representing 0.01% of the company’s voting rights. This transaction is part of the company’s ongoing compliance with UK MAR regulations, ensuring transparency in managerial transactions.
NIOX Group PLC, a company in the pharmaceutical industry, has announced that Keensight Capital will not make a firm offer for the company due to current macroeconomic conditions. Consequently, NIOX has decided to discontinue its Private Sale Process, as it is unlikely to achieve optimal outcomes for shareholders. Despite these developments, NIOX reported an 18% sales growth in the first quarter of the year and a net cash position of £15.4 million as of March 31, 2025.
NIOX Group plc, a company involved in the healthcare sector, has applied for a block admission of 6,862,848 ordinary shares to be traded on AIM at the London Stock Exchange. This move is part of the company’s 2022 Performance Share Plan Scheme, and the shares are expected to be admitted by 16 April 2025, aligning with existing shares and potentially impacting the company’s market presence.
NIOX Group plc, a company listed on the AIM market, has issued 363,006 new ordinary shares to its Executive Directors as part of its Deferred Share Bonus Plan. This issuance, related to the 2022 financial year’s annual bonus, follows the release of the company’s year-end results and marks the end of its closed period. The new shares are part of an existing block admission and align with the company’s remuneration policy, which defers a portion of bonuses for two years. This move reflects NIOX’s commitment to aligning executive incentives with shareholder interests, potentially impacting the company’s stock liquidity and executive shareholding structure.
NIOX Group PLC reported a 14% revenue growth to £41.8 million for the year ended 31 December 2024, with a 21% increase in adjusted EBITDA to £13.8 million. The company announced a proposal from Keensight Capital for a potential acquisition, though discussions are preliminary. Operationally, NIOX saw a 19% increase in NIOX® FeNO tests sold and is on track to launch the NIOX PRO® device in Q4 2025. The company is expanding its manufacturing capacity and distributor network, with plans to return 80% of free cash flow to shareholders, reflecting strong financial health and strategic growth initiatives.